RecruitingPhase 2NCT07308886
Recombinant Glycosylated Human Interleukin-7 (CYT107) for the Treatment of Kaposi Sarcoma in Participants With HIV and Immune Non-Response (REGIMENKS HIV)
Studying HIV-associated cancer
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Ramya M Ramaswami, M.D., MD, PhDNational Cancer Institute (NCI)
- Intervention
- CYT107(drug)
- Enrollment
- 55 enrolled
- Eligibility
- 18-120 years · All sexes
- Timeline
- 2026 – 2037
Study locations (1)
- National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT07308886 on ClinicalTrials.govOther trials for HIV-associated cancer
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05561595Transdiagnostic Intervention to Reduce Internalized Health-Related StigmaUniversity of Florida
- RECRUITINGPHASE1, PHASE2NCT06343311T-Cell Therapy (EB103) in Adults With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (NHL)Estrella Biopharma, Inc.
- ACTIVE NOT RECRUITINGNCT06480773Kaposi Sarcoma Chemotherapy and Research (KS-CARE)UNC Lineberger Comprehensive Cancer Center
- RECRUITINGPHASE1NCT04902443Pomalidomide and Nivolumab in People With Virus-Associated Malignancies With or Without HIVNational Cancer Institute (NCI)
- RECRUITINGPHASE1, PHASE2NCT04941274Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi SarcomaNational Cancer Institute (NCI)